Abstract
This study concerned the effects of ceruletide, a cholecystokinin (CCK)-related peptide, on amphetamine-stimulated behaviors (hyperlocomotion and stereotypy) and amphetamine-induced dopamine (DA) release from the striatum and the nucleus accumbens of the rat. Also, behavioral alterations due to ceruletide administration were compared with the change in DA release from these areas. Ceruletide 160 micrograms/kg s.c., attenuated hyperlocomotion induced by amphetamine, 1 mg/kg and 3 mg/kg s.c., but had no effect on amphetamine-induced stereotypy. Results from in vivo microdialysis experiments showed that s.c. administration of ceruletide caused a significant inhibition of the amphetamine-induced increase in DA release in the nucleus accumbens but not in the striatum. These neurochemical inhibitory effects of ceruletide disappeared completely with bilateral subdiaphragmatic vagotomy. However, infusion of 1 microM of ceruletide into the nucleus accumbens through the dialysis probe had no effect on amphetamine-induced DA release. These results suggest that the inhibitory effect of peripheral administration of ceruletide on amphetamine-induced hyperlocomotion is closely related to the change in DA release from the nucleus accumbens. In...Continue Reading
References
Dec 9, 1976·Nature·G J Dockray
Oct 16, 1975·Nature·J J VanderhaeghenW Gepts
Mar 1, 1991·Journal of Neurochemistry·F H MarshallJ C Hunter
Jan 1, 1989·Experimental Brain Research·K SeroogyJ Dixon
Mar 27, 1989·Brain Research·T HamamuraS Otsuki
Jan 1, 1985·Progress in Neuro-psychopharmacology & Biological Psychiatry·N P NairD M Bloom
Feb 18, 1986·European Journal of Pharmacology·K Matsubara
Jun 1, 1988·Pharmacology, Biochemistry, and Behavior·F WeissA Ettenberg
Sep 13, 1988·Brain Research·C A AltarP L Wood
Nov 1, 1987·Naunyn-Schmiedeberg's Archives of Pharmacology·B H WesterinkJ B de Vries
Apr 1, 1987·Neuropeptides·T Moroji, Y Hagino
Jan 20, 1987·Brain Research·T SharpU Ungerstedt
Jun 3, 1985·Brain Research·J N CrawleyL R Skirboll
Jan 1, 1981·Neuroscience·L R SkirbollB S Bunney
Mar 25, 1983·European Journal of Pharmacology·T NishikawaM Toru
Sep 16, 1983·European Journal of Pharmacology·J M Van ReeD De Wied
May 21, 1984·Brain Research·F J White, R Y Wang
May 1, 1980·Neuropharmacology·G Zetler
Jul 25, 1980·European Journal of Pharmacology·G Zetler
Aug 22, 1980·European Journal of Pharmacology·G Zetler
Aug 1, 1983·Pharmacology, Biochemistry, and Behavior·G GianutsosJ G Godfrey
May 18, 1984·European Journal of Pharmacology·K Matsubara, A Matsushita
Jan 1, 1980·Neuroscience·T HökfeltO Dann
Jan 1, 1987·Neurochemistry International·M RuggeriK Fuxe
Citations
Jan 29, 2000·European Journal of Pharmacology·C A TieppoA G Nasello
Mar 28, 1998·Neuropharmacology·J van Kampen, A J Stoessl
Apr 28, 2001·Pharmacology, Biochemistry, and Behavior·E E HuckeL F Felicio
Nov 5, 1998·Pharmacology, Biochemistry, and Behavior·K EtouH Uchimura
Jul 18, 2001·Peptides·C A TieppoA G Nasello
Feb 25, 2000·Neuroscience Letters·P D ShillingJ R Kelsoe
Aug 23, 2003·Neuroscience Letters·David FeifelDavid S Segal
May 1, 1996·Pharmacology & Toxicology·S A BorisenkoP T Männistö
Mar 1, 1996·The International Journal of Neuroscience·C Başar-ErogluG Zetler